Cited by 5,051Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and ManagementAcute Ischemic Stroke Management

The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

Ruff, Christian T, Giugliano, Robert P, Braunwald, Eugene, Hoffman, Elaine B, Deenadayalu, Naveen, Ezekowitz, Michael D, Camm, A John, Weitz, Jeffrey I, Lewis, Basil S, Parkhomenko, Alexander, Yamashita, Takeshi, Antman, Elliott M·2014·The Lancet

DOI 10.1016/s0140-6736(13)62343-0

Open this paper in CoChat — free account

Abstract

Background Four new oral anticoagulants compare favourably with warfarin for stroke prevention in patients with atrial fibrillation; however, the balance between efficacy and safety in subgroups needs better definition. We aimed to assess the relative benefit of new oral anticoagulants in key subgroups, and the effects on important secondary outcomes.Methods We searched Medline from Jan 1, 2009, to Nov 19, 2013, limiting searches to phase 3, randomised trials of patients with atrial fibrillation who were randomised to receive new oral anticoagulants or warfarin, and trials in which both efficacy and safety outcomes were reported. We did a prespecified meta-analysis of all 71,683 participants included in the RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48 trials. The main outcomes were stroke and systemic embolic events, ischaemic stroke, haemorrhagic stroke, all-cause mortality, myocardial infarction, major bleeding, intracranial haemorrhage, and gastrointestinal bleeding. We calculated relative risks (RRs) and 95% CIs for each outcome. We did subgroup analyses to assess whether differences in patient and trial characteristics affected outcomes. We used a random-effects model to compare pooled outcomes and tested for heterogeneity.Findings 42,411 participants received a new oral anticoagulant and 29,272 participants received warfarin. New oral anticoagulants significantly reduced stroke or systemic embolic events by 19% compared with warfarin (RR 0·81, 95% CI 0·73-0·91; p<0·0001), mainly driven by a reduction in haemorrhagic stroke (0·49, 0·38-0·64; p<0·0001). New oral anticoagulants also significantly reduced all-cause mortality (0·90, 0·85-0·95; p=0·0003) and intracranial haemorrhage (0·48, 0·39-0·59; p<0·0001), but increased gastrointestinal bleeding (1·25, 1·01-1·55; p=0·04). We noted no heterogeneity for stroke or systemic embolic events in important subgroups, but there was a greater relative reduction in major bleeding with new oral anticoagulants when the centre-based time in therapeutic range was less than 66% than when it was 66% or more (0·69, 0·59-0·81 vs 0·93, 0·76-1·13; p for interaction 0·022). Low-dose new oral anticoagulant regimens showed similar overall reductions in stroke or systemic embolic events to warfarin (1·03, 0·84-1·27; p=0·74), and a more favourable bleeding profile (0·65, 0·43-1·00; p=0·05), but significantly more ischaemic strokes (1·28, 1·02-1·60; p=0·045).Interpretation This meta-analysis is the first to include data for all four new oral anticoagulants studied in the pivotal phase 3 clinical trials for stroke prevention or systemic embolic events in patients with atrial fibrillation. New oral anticoagulants had a favourable risk-benefit profile, with significant reductions in stroke, intracranial haemorrhage, and mortality, and with similar major bleeding as for warfarin, but increased gastrointestinal bleeding. The relative efficacy and safety of new oral anticoagulants was consistent across a wide range of patients. Our findings offer clinicians a more comprehensive picture of the new oral anticoagulants as a therapeutic option to reduce the risk of stroke in this patient population.Funding None.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(13)62343-0

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Kirchhof, P. F., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Gelder, I. C. V., Al‐Attar, N., Hindricks, G., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq278 · Cited by 5,924
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation
Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J. G. M., & Lip, G. Y. H. (2010) · CHEST Journal · doi:10.1378/chest.10-0134 · Cited by 4,517

Show all 45 references

Sorted by citations

Items 201–300 of 1,004

Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry
Lip, G. Y. H., Laroche, C., Popescu, M. I., Rasmussen, L. H., Vitali-Serdoz, L., Dan, G.-A., Kalarus, Z., Crijns, H. J. G. M., Oliveira, M. M., Tavazzi, L., et al. (2015) · Europace · doi:10.1093/europace/euv269 · Cited by 151
Reversal of anticoagulants: an overview of current developments
Thiele, T., Selleng, K., & Greinacher, A. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-11-0982 · Cited by 150
Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
Zuily, S., Cohen, H., Isenberg, D. A., Woller, S. C., Crowther, M. A., Dufrost, V., Wahl, D. G., Doré, C. J., Cuker, A. C., Carrier, M., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14935 · Cited by 160
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1
Diener, H., Aisenberg, J., Ansell, J., Atar, D., BREITHARDT, G. E., Eikelboom, J. W., Ezekowitz, M. D., Granger, C. B., Halperin, J. L., Hohnloser, S. H., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv643 · Cited by 147
Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation
Zirlik, A., & Bode, C. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1446-0 · Cited by 158
Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis
Nagaoki, Y., Aikata, H., Daijo, K., Teraoka, Y., Shinohara, F., Nakamura, Y., Hatooka, M., Morio, K., Nakahara, T., Kawaoka, T., et al. (2017) · Hepatology Research · doi:10.1111/hepr.12895 · Cited by 146
Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease
Ha, J. T. K., Neuen, B. L., Cheng, L. P., Jun, M., Toyama, T., Gallagher, M., Jardine, M., Sood, M. M., Garg, A. X., Palmer, S. C., et al. (2019) · Annals of Internal Medicine · doi:10.7326/m19-0087 · Cited by 155
Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants
Camm, A. J., Cools, F. J. S., Virdone, S., Bassand, J., Fitzmaurice, D. A., Fox, K. A. A., Goldhaber, S. Z., Goto, S., Haas, S. K., Mantovani, L. G., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.07.045 · Cited by 148
Laboratory Monitoring of Direct Oral Anticoagulants (DOACs)
Dunois-Lardé, C. (2021) · Biomedicines · doi:10.3390/biomedicines9050445 · Cited by 148
Select Drug-Drug Interactions With Direct Oral Anticoagulants
Wiggins, B. S., Dixon, D. L., Neyens, R. R., Page, R. L., II, & Gluckman, T. J. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.12.068 · Cited by 144
Safety and efficacy of well managed warfarin
Sjögren, V., Grzymala-Lubanski, B., Renlund, H., Friberg, L., Lip, G. Y. H., Svensson, P. J., & Själander, A. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-10-0859 · Cited by 145
Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis
Halvorsen, S., Storey, R. F., Rocca, B., Sibbing, D., ten Berg, J. M., Grove, E. L., Weiss, T. W., Collet, J., Andreotti, F., Gulba, D. C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw454 · Cited by 148
Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation
Eikelboom, J. W., Quinlan, D. J., Hirsh, J., Connolly, S. J., & Weitz, J. I. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.0364 · Cited by 145
Prior Anticoagulation in Patients with Ischemic Stroke and Atrial Fibrillation
Meinel, T. R., Branca, M., Marchis, G. M. D., Nedeltchev, K., Kahles, T., Bonati, L. H., Arnold, M., Heldner, M. R., Jung, S. C., Carrera, E., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25917 · Cited by 142
American College of Surgeons’ Guidelines for the Perioperative Management of Antithrombotic Medication
Hornor, M. A., Duane, T. M., Ehlers, A. P., Jensen, E. H., Brown, P. S., Pohl, D., Costa, P., Ko, C. Y., & Laronga, C. (2018) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2018.08.183 · Cited by 143
A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation
Cowan, J. C., Wu, J., Hall, M., Orlowski, A., West, R. M., & Gale, C. P. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy411 · Cited by 142
Anticoagulation in chronic kidney disease: from guidelines to clinical practice
Aursulesei, V., & Costache, I. I. (2019) · Clinical Cardiology · doi:10.1002/clc.23196 · Cited by 142
A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference
Kirchhof, P. F., BREITHARDT, G. E., Bax, J. J., Benninger, G., Blomström‐Lundqvist, C., Boriani, G., Brandes, A., Brown, H., Brueckmann, M., Calkins, H. G., et al. (2015) · EP Europace · doi:10.1093/europace/euv304 · Cited by 143
Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy
Barra, M. E., Fanikos, J. R., Connors, J. M., Sylvester, K. W., Piazza, G., & Goldhaber, S. Z. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.05.041 · Cited by 141
Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Atrial Fibrillation
Cha, M., Choi, E., Han, K., Lee, S., Lim, W., Oh, S., & Lip, G. Y. H. (2017) · Stroke · doi:10.1161/strokeaha.117.018773 · Cited by 140
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2
Diener, H., Aisenberg, J., Ansell, J., Atar, D., BREITHARDT, G. E., Eikelboom, J. W., Ezekowitz, M. D., Granger, C. B., Halperin, J. L., Hohnloser, S. H., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw069 · Cited by 142
Reversal agents for non-vitamin K antagonist oral anticoagulants
Levy, J. H., Douketis, J. D., & Weitz, J. I. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.223 · Cited by 141
2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation
Chiang, C., Wu, T.-J., Ueng, K.-C., Chao, T., Chang, K., Wang, C.-C., Lin, Y., Yin, W., Kuo, J., Lin, W., et al. (2016) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2016.10.005 · Cited by 138
Association of prothrombin complex concentrate administration and hematoma enlargement in non–vitamin K antagonist oral anticoagulant–related intracerebral hemorrhage
Gerner, S. T., Kuramatsu, J. B., Sembill, J. A., Sprügel, M. I., Endres, M., Hæusler, K. G., Vajkoczy, P., Ringleb, P. A., Purrucker, J. C., Rizos, T., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25134 · Cited by 138
Editor's Choice - Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials
Kakkos, S. K., Kirkilesis, G. I., & Tsolakis, I. A. (2014) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2014.05.001 · Cited by 140
2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation
Барбараш, О. Л., Duplyakov, D. V., Zateischikov, D. A., Панченко, Е. П., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Sa, A., Alekyan, B. G., Викторович, А. М., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4449 · Cited by 147
Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs
Verheugt, F. W. A., & Granger, C. B. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60245-8 · Cited by 137
Atrial Fibrillation and Ventricular Arrhythmias
Gillis, A. M. (2017) · Circulation · doi:10.1161/circulationaha.116.025312 · Cited by 135
European Stroke Organisation (ESO) guideline on screening for subclinical atrial fibrillation after stroke or transient ischaemic attack of undetermined origin
Rubiera, M., Aires, A., Antonenko, K., Lémeret, S., Nolte, C. H., Jukka Putaala, A., Schnabel, R. B., Tuladhar, A. M., Werring, D. J., Zeraatkar, D., et al. (2022) · European Stroke Journal · doi:10.1177/23969873221099478 · Cited by 136
JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias
Ono, K., Iwasaki, Y., Akao, M., Ikeda, T., Ishii, K., Inden, Y., Kusano, K., Kobayashi, Y., Koretsune, Y., Sasano, T., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-20-1212 · Cited by 132
Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis
Proietti, M., Romanazzi, I., Romiti, G. F., Farcomeni, A., & Lip, G. Y. H. (2018) · Stroke · doi:10.1161/strokeaha.117.018395 · Cited by 126
Importance of Considering Competing Risks in Time-to-Event Analyses
Abdel-Qadir, H. M., Fang, J., Lee, D. S., Tu, J. V., Amir, E., Austin, P. C., & Anderson, G. (2018) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.004580 · Cited by 127
Trends in Cardiovascular Mortality Related to Atrial Fibrillation in the United States, 2011 to 2018
Tanaka, Y., Shah, N. S., PASSMAN, R. S., Greenland, P., Lloyd‐Jones, D. M., & Khan, S. S. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020163 · Cited by 128
Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction
Potpara, T., Ferro, C. J., & Lip, G. Y. H. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2018.19 · Cited by 130
Oral Anticoagulant Type and Outcomes After Transcatheter Aortic Valve Replacement
Jochheim, D., Barbanti, M., Capretti, G., Stefanini, G. G., Hapfelmeier, A., Zadrozny, M., Baquet, M., Fischer, J., Theiss, H. D., Todaro, D., et al. (2019) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2019.03.003 · Cited by 128
Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.11.027 · Cited by 147
Spotlight on the 2024 ESC/EACTS management of atrial fibrillation guidelines: 10 novel key aspects
Rienstra, M., Tzeis, S., Bunting, K. V., Caso, V., Crijns, H. J. G. M., De Potter, T. J. R., Sanders, P., Svennberg, E., Casado-Arroyo, R., Dwight, J., et al. (2024) · Europace · doi:10.1093/europace/euae298 · Cited by 128
Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) in Patients with Concomitant Atrial Fibrillation and Heart Failure: A Systemic Review and Meta-Analysis of Randomized Trials
Xiong, Q., Lau, Y. C., Senoo, K., Lane, D. A., Hong, K., & Lip, G. Y. H. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.343 · Cited by 127
Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation
Bai, Y., Deng, H., Shantsila, A., & Lip, G. Y. H. (2017) · Stroke · doi:10.1161/strokeaha.116.016275 · Cited by 128
The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction
Jones, D. A., Wright, P., Alizadeh, M. A., Fhadil, S., Rathod, K. S., Guttmann, O. P., Knight, C. J., Timmis, A., Baumbach, A., Wragg, A., et al. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa096 · Cited by 124
EHRA expert consensus document on the management of arrhythmias in frailty syndrome, endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)
Savelieva, I., Fumagalli, S., Kenny, R. A., Anker, S. D., Bénétos, A., Boriani, G., Bunch, T. J., Dagres, N., Dubner, S., Fauchier, L., et al. (2022) · EP Europace · doi:10.1093/europace/euac123 · Cited by 137
Genotype-Guided vs Clinical Dosing of Warfarin and Its Analogues
Stergiopoulos, K., & Brown, D. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.2368 · Cited by 125
Characteristics of Intracerebral Hemorrhage During Rivaroxaban Treatment
Hagii, J., Tomita, H., Metoki, N., Saito, S., Shiroto, H., Hitomi, H., Kamada, T., Seino, S., Takahashi, K., Baba, Y., et al. (2014) · Stroke · doi:10.1161/strokeaha.114.006661 · Cited by 125
Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease
Renda, G., Ricci, F., Giugliano, R. P., & Caterina, R. D. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.12.038 · Cited by 131
Early Rhythm Control in Patients With Atrial Fibrillation and High Comorbidity Burden
Rillig, A., Borof, K., BREITHARDT, G. E., Camm, A. J., Crijns, H. J. G. M., Goette, A., Kück, K., Metzner, A., Vardas, P. E., Vettorazzi, E., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.060274 · Cited by 125
Left atrial appendage occlusion
Holmes, D. R., Korsholm, K., Rodés‐Cabau, J., Saw, J., Berti, S. L., & Alkhouli, M. A. (2023) · EuroIntervention · doi:10.4244/eij-d-22-00627 · Cited by 126
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation
Ruff, C. T., Patel, S. M., Giugliano, R. P., Morrow, D. A., Hug, B. A., Kuder, J., Goodrich, E. L., Chen, S.-A., Goodman, S. G., Joung, B., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2406674 · Cited by 124
Antidotes for Novel Oral Anticoagulants: Current Status and Future Potential
Crowther, M., & Crowther, M. A. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303402 · Cited by 120
Current Status and Outcomes of Direct Oral Anticoagulant Use in Real-World Atrial Fibrillation Patients ― Fushimi AF Registry ―
Yamashita, Y., Uozumi, R., Hamatani, Y., Esato, M., Chun, Y., Tsuji, H., Wada, H., Hasegawa, K., Ogawa, H., Abe, M., et al. (2017) · Circulation Journal · doi:10.1253/circj.cj-16-1337 · Cited by 124
Trends in Use of Oral Anticoagulants in Older Adults With Newly Diagnosed Atrial Fibrillation, 2010-2020
Ko, D., Lin, K. J., Bessette, L. G., Lee, S. B., Walkey, A. J., Cheng, S. C., Kim, E., Glynn, R. J., & Kim, D. H. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.42964 · Cited by 132
Early start of DOAC after ischemic stroke
Seiffge, D. J., Traenka, C., Polymeris, A. A., Hert, L., Peters, N., Lyrer, P. A., Engelter, S. T., Bonati, L. H., & Marchis, G. M. D. (2016) · Neurology · doi:10.1212/wnl.0000000000003283 · Cited by 124
Management of Atrial Fibrillation in Patients 75 Years and Older
Volgman, A. S., Nair, G. G., Lyubarova, R., Merchant, F. M., Mason, P. K., Curtis, A. B., WENGER, N. K., Aggarwal, N. T., Kirkpatrick, J. N., & Benjamin, E. J. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.10.037 · Cited by 124
Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants
Meinel, T. R., Wilson, D., Gensicke, H., Scheitz, J. F., Ringleb, P. A., Goganau, I., Kaesmacher, J., Bae, H., Kim, D. Y., Kermer, P., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2022.4782 · Cited by 121
Clinical Outcomes Associated With Left Atrial Appendage Occlusion Versus Direct Oral Anticoagulation in Atrial Fibrillation
Nielsen‐Kudsk, J. E., Korsholm, K., Damgaard, D., Valentin, J. B., Diener, H., Camm, A. J., & Johnsen, S. P. (2021) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2020.09.051 · Cited by 120
Cerebral Amyloid Angiopathy–Related Transient Focal Neurologic Episodes
Smith, E. E., Charidimou, A., Ayata, C., Werring, D. J., & Greenberg, S. M. (2021) · Neurology · doi:10.1212/wnl.0000000000012234 · Cited by 121
Long-term Thromboembolic Risk in Patients With Postoperative Atrial Fibrillation After Coronary Artery Bypass Graft Surgery and Patients With Nonvalvular Atrial Fibrillation
Butt, J. H., Xian, Y., Peterson, E. D., Olsen, P. S., Rørth, R., Gundlund, A., Olesen, J. B., Gislason, G., Torp-Pedersen, C. T., Køber, L., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.0405 · Cited by 120
Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial
Rao, M. P., Vinereanu, D., WOJDYLA, D. M., Alexander, J. H., Atar, D., Hylek, E. M., Hanna, M., Wallentin, L. C., Lópes, R. D., Gersh, B. J., et al. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.10.036 · Cited by 118
Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs
Patti, G., Cavallari, I., Andreotti, F., Calabrò, P., Cirillo, P. L., Denas, G., Galli, M., Golia, E., Maddaloni, E., Marcucci, R., et al. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0080-2 · Cited by 122
Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial
Guo, Y., Lane, D. A., Chen, Y., & Lip, G. Y. H. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.03.019 · Cited by 119
Use of Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation Who Have a History of Intracranial Hemorrhage
Chao, T., Liu, C., Liao, J., Wang, K.-L., Lin, Y., Chang, S., Lo, L., Hu, Y., Tuan, T., Chung, F., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.019794 · Cited by 117
Management of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society (LAHRS)
Arnar, D. O., Mairesse, G. H., Boriani, G., Calkins, H. G., Chin, A., Coats, A. J. S., Deharo, J., Svendsen, J. H., Heidbüchel, H., Isa, R., et al. (2019) · EP Europace · doi:10.1093/europace/euz046 · Cited by 127
Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial
Salman, R. A., Keerie, C., Stephen, J., Lewis, S. C., Norrie, J. D., Dennis, M. S., Newby, D. E., Wardlaw, J. M., Lip, G. Y. H., Parry‐Jones, A., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00264-7 · Cited by 117
Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant type
Wilson, D., Charidimou, A., Shakeshaft, C., Ambler, G., White, M. J., Cohen, H., Yousry, T. A., Salman, R. A., Lip, G. Y. H., Brown, M. M., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002310 · Cited by 116
Atrial Fibrillation and Ischemic Stroke: A Clinical Review
Migdady, I., Russman, A., & Buletko, A. B. (2021) · Seminars in Neurology · doi:10.1055/s-0041-1726332 · Cited by 130
Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper
Gorog, D. A., Gue, Y. X., Chao, T., Fauchier, L., Ferreiro, J. L., Huber, K., Konstantinides, S., Lane, D. A., Marín, F. R., Oldgren, J., et al. (2022) · Thrombosis and Haemostasis · doi:10.1055/s-0042-1750385 · Cited by 116
European Stroke Organisation (ESO) and European Association of Neurosurgical Societies (EANS) guideline on stroke due to spontaneous intracerebral haemorrhage
Steiner, T., Purrucker, J. C., de Sousa, D. A., Apostolaki‐Hansson, T., Beck, J., Christensen, H., Cordonnier, C., Downer, M. B., Eilertsen, H., Gartly, R., et al. (2025) · European Stroke Journal · doi:10.1177/23969873251340815 · Cited by 140
Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: DAWA Pilot Study
Durães, A. R., Roriz, P. D. S., Nunes, B. D. A., Albuquerque, F. P. E., de Bulhões, F. V., Fernandes, A. M. S., & Aras, R. (2016) · Drugs in R&D · doi:10.1007/s40268-016-0124-1 · Cited by 114
How I treat CLL patients with ibrutinib
Brown, J. R. (2017) · Blood · doi:10.1182/blood-2017-08-764712 · Cited by 114
Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?
Lippi, G., & Favaloro, E. J. (2014) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-0767 · Cited by 113
Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events
Rost, N. S., Giugliano, R. P., Ruff, C. T., Murphy, S. A., Crompton, A. E., Norden, A. D., Silverman, S. B., Singhal, A. B., Nicolau, J. C., SomaRaju, B., et al. (2016) · Stroke · doi:10.1161/strokeaha.116.013540 · Cited by 114
Evaluation of andexanet alfa and four‐factor prothrombin complex concentrate (4F‐PCC) for reversal of rivaroxaban‐ and apixaban‐associated intracranial hemorrhages
Barra, M. E., Das, A. S., Hayes, B. D., Rosenthal, E. S., Rosovsky, R. P. G., Fuh, L., Patel, A. B., Goldstein, J. N., & Roberts, R. J. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14838 · Cited by 113
Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation
Cameron, C. G., Coyle, D., Richter, T. A., Kelly, S., Gauthier, K., Steiner, S., Carrier, M., Coyle, K., Bai, A., Moulton, K., et al. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-004301 · Cited by 113
Edoxaban in Asian Patients With Atrial Fibrillation
Lee, S., Choi, E., Han, K., Jung, J., Oh, S., & Lip, G. Y. H. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.05.066 · Cited by 112
Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI48 Trial
Xu, H., Ruff, C. T., Giugliano, R. P., Murphy, S. A., Nordio, F., Patel, I. J., Shi, M., Mercuri, M. F., Antman, E. M., & Braunwald, E. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002587 · Cited by 111
The growing clinical spectrum of cerebral amyloid angiopathy
Wermer, M. J. H., & Greenberg, S. M. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000510 · Cited by 117
Recanalization Therapies in Acute Ischemic Stroke Patients
Seiffge, D. J., Hooff, R. V., Nolte, C. H., Béjot, Y., Turc, G., Ikenberg, B. D., Berge, E., Persike, M., Dequatre‐Ponchelle, N., Strbian, D., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.015484 · Cited by 111
Practical Management of Anticoagulation in Patients With Atrial Fibrillation
Kovacs, R. J., Flaker, G. C., Saxonhouse, S. J., Doherty, J. U., Birtcher, K. K., Cuker, A. C., Davidson, B. L., Giugliano, R. P., Granger, C. B., Jaffer, A. K., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.01.049 · Cited by 114
Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial
Ng, K. H., Shestakovska, O., Connolly, S. J., Eikelboom, J. W., Avezum, Á., Díaz, R., Lanas, F. T., Yusuf, S., & Hart, R. G. (2015) · Age and Ageing · doi:10.1093/ageing/afv156 · Cited by 113
Temporal trends and patterns in atrial fibrillation incidence: A population-based study of 3·4 million individuals
Wu, J., Nadarajah, R., Nakao, Y. M., Nakao, K., Wilkinson, C., Mamas, M. A., Camm, A. J., & Gale, C. P. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100386 · Cited by 110
Peptic ulcer disease
Almadi, M. A., Lu, Y., Alali, A. A., & Barkun, A. N. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00155-7 · Cited by 133
Evolving Treatments for Arterial and Venous Thrombosis
Chan, N., Eikelboom, J. W., & Weitz, J. I. (2016) · Circulation Research · doi:10.1161/circresaha.116.306925 · Cited by 113
Atrial cardiopathy: a mechanism of cryptogenic stroke
Yaghi, S. R., Kamel, H., & Elkind, M. S. V. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2017.1355238 · Cited by 109
Antithrombotic Therapy and Device-Related Thrombosis Following Endovascular Left Atrial Appendage Closure
Saw, J., Nielsen‐Kudsk, J. E., Bergmann, M., Daniels, M. J., Tzikas, A., Reisman, M., & Rana, B. S. (2019) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2018.11.001 · Cited by 111
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
Martinez, B. K., Sood, N. A., Bunz, T. J., & Coleman, C. I. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008643 · Cited by 111
Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score: A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy
Skjøth, F., Nielsen, P., Larsen, T. B., & Lip, G. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-07-0565 · Cited by 106
Trends in Oral Anticoagulant Choice for Acute Stroke Patients with Nonvalvular Atrial Fibrillation in Japan: The SAMURAI-NVAF Study
Toyoda, Ḱ., Arihiro, S., Todo, K., Yamagami, H., Kimura, K., Furui, E., Terasaki, T., Shiokawa, Y., Kamiyama, K., Takizawa, S., et al. (2015) · International Journal of Stroke · doi:10.1111/ijs.12452 · Cited by 108
Laboratory Testing in the Era of Direct or Non–Vitamin K Antagonist Oral Anticoagulants: A Practical Guide to Measuring Their Activity and Avoiding Diagnostic Errors
Lippi, G., & Favaloro, E. J. (2015) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0035-1546827 · Cited by 107
Contemporary Atrial Fibrillation Management: A Comparison of the Current AHA/ACC/HRS, CCS, and ESC Guidelines
Andrade, J. G., Macle, L., Nattel, S., Verma, A., & Cairns, J. A. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.06.002 · Cited by 107
Therapeutic endoscopy-related GI bleeding and thromboembolic events in patients using warfarin or direct oral anticoagulants: results from a large nationwide database analysis
Nagata, N., Yasunaga, H., Matsui, H., Fushimi, K., Watanabe, K., Akiyama, J., Uemura, N., & Niikura, R. (2017) · Gut · doi:10.1136/gutjnl-2017-313999 · Cited by 108
Brain microbleeds, anticoagulation, and hemorrhage risk
Charidimou, A., Karayiannis, C., Song, T., Örken, D. N., Thijs, V., Lemmens, R., Kim, J., Goh, S. M., Phan, T. G., Soufan, C., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004704 · Cited by 107
Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial
Chao, T., Chen, S., Ruff, C. T., Hamershock, R. A., Mercuri, M. F., Antman, E. M., Braunwald, E., & Giugliano, R. P. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy807 · Cited by 106
Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation
Seiffge, D. J., Paciaroni, M., Wilson, D., Koga, M., Macha, K., Cappellari, M., Schaedelin, S. A., Shakeshaft, C., Takagi, M., Tsivgoulis, G. K., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25489 · Cited by 108
Stroke Prevention in Atrial Fibrillation
Katsanos, A. H., Kamel, H., Healey, J. S., & Hart, R. G. (2020) · Circulation · doi:10.1161/circulationaha.120.049768 · Cited by 108
Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting
Michalski, F., Tittl, L., Middeldorp, S., Cohen, H., Kadir, R. A., Arachchillage, D. J., Arya, R., Ay, C., Marten, S., & Beyer‐Westendorf, J. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-04-0305 · Cited by 106
Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the United States
Lip, G. Y. H., Pan, X., Kamble, S., Kawabata, H., Mardekian, J., Masseria, C., Bruno, A. S., & Phatak, H. M. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12863 · Cited by 106
The Assessment of the Watchman Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) trial
Holmes, D. R., Reddy, V. Y., Buchbinder, M., Steín, K. M., Elletson, M., Bergmann, M., Schmidt, B., & Saw, J. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.03.007 · Cited by 109
Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Slot, K. B., & Berge, E. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008980.pub2 · Cited by 109
National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018
Brieger, D. B., Amerena, J. V., Attia, J., Bajorek, B. V., Chan, K. H., Connell, C., Freedman, B., Ferguson, C., Hall, T. L., Haqqani, H. M., et al. (2018) · The Medical Journal of Australia · doi:10.5694/mja18.00646 · Cited by 110
Antithrombotic Therapy for Primary and Secondary Prevention of Ischemic Stroke
Greco, A., Occhipinti, G., Giacoppo, D., Agnello, F. G., Laudani, C., Spagnolo, M., Mauro, M. S., Rochira, C., Finocchiaro, S., Mazzone, P. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.07.025 · Cited by 115
New developments in anticoagulants: Past, present and future
Weitz, J. I., & Harenberg, J. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-10-0807 · Cited by 105

Authors: Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., Yamashita, T., & Antman, E. M.
Affiliations: Brigham and Women's Hospital (US)
Thomas Jefferson University (US)
St George's, University of London (GB)
Thrombosis and Atherosclerosis Research Institute (CA)
Carmel Medical Center (IL)
Cardiovascular Institute Hospital (JP)
Corresponding author: Ruff, Christian T
ORCID: Ruff, Christian T
Giugliano, Robert P
Ezekowitz, Michael D
Camm, A John
Weitz, Jeffrey I
Lewis, Basil S
Parkhomenko, Alexander
Yamashita, Takeshi
Antman, Elliott M
Venue: The Lancet
Publisher: Elsevier BV
Published: 2014-03
Volume: 383
Issue: 9921
Pages: 955-962
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(13)62343-0
OpenAlex: W2152623033
Cited by: 5,051
References: 45
Citations by year: 2026: 249 · 2025: 310 · 2024: 399 · 2023: 426 · 2022: 410 · 2021: 490 · 2020: 521 · 2019: 462 · 2018: 456 · 2017: 447 · 2016: 406 · 2015: 318 · 2014: 139
FWCI: 49.57
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
Keywords: direct oral anticoagulants, warfarin, atrial fibrillation, stroke prevention, systemic embolism, hemorrhagic stroke, intracranial hemorrhage, gastrointestinal bleeding, major bleeding, all-cause mortality, subgroup analysis, factor Xa inhibitors, dabigatran, rivaroxaban, apixaban
MeSH terms: Administration, Oral, Anticoagulants, Atrial Fibrillation, Embolism, Humans, Warfarin, Randomized Controlled Trials as Topic, Treatment Outcome, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks